Treatment of thyrotropin-secreting pituitary adenomas with octreotide

Endocrine Journal

Volumn 46, Issue 1, 1999, Pages 113-123

  Shimatsu, Akira ^a   Murabe, Hiroyuki ^a   Kamoi, Kyuzi ^b   Suzuki, Yoshikazu ^c   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGAOKA RED CROSS HOSPITAL   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hyperthyroidism; Octreotide; Tachyphylaxis; Thyrotropin secreting pituitary adenoma; Tumor shrinkage; Subunit

Indexed keywords

OCTREOTIDE; SOMATOSTATIN RECEPTOR; THYROTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS ADENOMA; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYPHYLAXIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0032918063     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.46.113     Document Type: Article

References (50)

1. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17: 610-638.
2. McCutcheon IE, Weintraub BD, Oldfield EH (1990) Surgical treatment of thyrotropin-secreting pituitary adenomas. J Neurosurg 73: 674-683.
3. Wollesen F, Andersen T, Karle A (1982) Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Ann Intern Med 96: 281-286.
4. McLellan AR, Connell JM, Alexander WD, Davies DL (1988) Clinical response of thyrotropin-secreting macroadenoma to bromocriptine and radiotherapy. Acta Endocrinol (Copenh) 119: 189-194.
5. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E (1985) Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. New Engl J Med 313: 1576-1580.
6. Shimatsu A, Imura H, Irie M, Nakagawa S, Goto Y, Shimizu N, Takeda R, Kato Y, Saito S, Ibayashi H, Nawata S, Shizume K, Uozumi T (1989) A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism. Folia Endocrinol Japon 65: 640-652 (In Japanese).
7. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. New Engl J Med 317: 12-17.
8. Chanson P, Weintraub BD, Harris AG (1993) Octreotide therapy for thyroid-stimulating hormne-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119: 236-240.
9. Kamoi K, Mitsuma T, Sato H, Yokoyama M, Washiyama K, Tanaka R, Arai O, Takasu N, Yamada T (1985) Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves' disease in a middle-aged woman. Acta Endocrinol (Copenh) 110: 373-382.
10. Usui T, Sako Y, Matsumoto M, Kita T, Shimatsu A, Imura H (1989) A case of thyrotropin-, growth hormone-, and prolactin-secreting pituitary adenoma with a remarkable response to long-acting somatostatin analogue (SMS 201-995). Jpn J Soc Int Med 78: 1605-1606 (In Japanese).
11. Suzuki Y, Nanno M, Gemma R, Oki Y, Tanaka I, Taminato T, Shimatsu A, Ninchoji T, Yoshimi T (1992) Marked inhibition of hormonal secretion and tumor shrinkage by long-acting somatostatin analogue octreotide in a patient with a TSH- and GH-secreting pituitary adenoma. Jpn Arch Int Med 39: 329-336.
12. Assadian H, Shimatsu A, Koshiyama H, Hattori N, Ishikawa Y, Tanoh T, Imura H (1990) Secretion of alpha and TSH-beta subunits in patients with acromegaly: An in vivo study. Acta Endocrinol (Copenh) 122: 729-734.
13. Shimatsu A, Murabe H, Sasaki S, Hattori N, Tanoh T, Imura H (1990) Secretory dynamics of growth hormone in an acromegalic patient associated with Graves' disease. J Clin Endocrinol Metab 71: 1059-1063.
14. Murabe H, Shimatsu A, Ihara C, Mizuta H, Nakamura Y, Nagata I, Kikuchi H, Nakao K (1996) Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: Quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction. J Neuroendocrinol 8: 605-610.
15. Kourides IA Ridgway EC, Weintraub BD, Bigos ST, Gershengorn MC, Maloof F (1977) Thyrotropin-induced hyperthyroidism: Use of alpha and beta subunit levels to identify patients with pituitary tumors. J Clin Endocrinol Metab 45: 534-543.
16. Beckers A, Abs R, Mahler C, Vandalem JL, Pirens G, Hennen G, Stevenaert A (1991) Thyrotropin-secreting pituitary adenomas: Report of seven cases. J Clin Endocrinol Metab 72: 477-483.
17. Caron P, Gerbeau C, Pradayrol L, Simonetta C, Bayard F (1996) Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Clin Endocrinol Metab 81: 1164-1168.
18. Levy A, Eckland DJA, Gurney AM, Reubi JC, Doshi R, Lightman SL (1989) Somatostatin and thyrotrophin-releasing hormone response and receptor status of a thyrotrophin-secreting pituitary adenoma: Clinical and in vitro studies. J Neuroendocrinol 1: 321-326.
19. Polak M, Bertherat J, Li JY, Kujas M, LeDafniet M, Weizani H, Van Effenterre R, Epelbaum J, Turpin G (1991) A human TSH-secreting adenoma: Endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201-995 treatment. Acta Endocrinol (Copenh) 124: 479-486.
20. Bertherat J, Brue J, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J (1992) Somatostatin receptors on thyrotropin-secreting pituitary adenomas: Comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab 75: 540-546.
21. Beck-Peccoz P, Mariotti S, Guillausseau PJ, Medri G, Piscitelli G, Bertoli A, Barbarino A, Rondena M, Chanson P, Pinchera A, Faglia G (1989) Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 68: 208-214.
22. Chayen SD, Gross D, Makhoul O, Glaser B (1992) TSH producing pituitary tumor: Biochemical diagnosis and long-term medical management with octreotide. Horm Metab Res 24: 34-38.
23. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, Melmed S (1992) Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117: 711-718.
24. Wemeau JL, Dewailly D, Leroy R, D'Herbomez M, Mazzuca M, Decoulx M, Jaquet P (1988) Long-term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 66: 636-639.
25. Sassolas G, Serusclat P, Claustrat B, Trouillas J, Merabet S, Cohen R, Souquet JC (1988) Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201-995). Horm Res 29: 124-128.
26. Warnet A, Lajeunie E, Gelbert F, Duet M, Chanson P, Cophignon J, Harris AG (1991) Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995). Acta Endocrinol (Copenh) 124: 487-491.
27. De Rosa G, Testa A, Ciacomini D, Carrozza C (1994) Escape phenomenon after successful bromocriptine and octreotide treatment in thyroid stimulating hormone secreting pituitary adenoma residual tissue. Eur J Cancer 30A: 247-248.
28. Shimatsu A, Imura H, Irie M, Nakagawa S, Goto Y, Shimizu N, Takeda R, Kato Y, Saito S, Ibayashi H, Nawata H, Shizume K, Uozumi T (1992) Long-term treatment of acromegaly and gigantism with octreotide (SMS 201-995). Folia Endocrinol Japon 68: 89-99 (In Japanese).
29. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G, Italian Multicenter Octreotide Study Group (1995) Effects of treatment with octreotide in acromegalic patients - A multicenter Italian study. Eur J Endocrinol 133: 430-439.
30. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson IMD, Vance ML, Thorner MO, Ho PJ, Jaffe CA, Frohman LA, Kleinberg DL (1995) Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study. J Clin Endocrinol Metab 80: 2768-2775.
31. Koelz A, Kraenzlin M, Gyr K, Meier V, Bloom SR, Heitz P, Stalder H (1987) Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma. Gastroenterology 92: 527-531.
32. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New Engl J Med 315: 663-666.
33. Hukovic N, Panetta R, Kumar U, Patel YC (1996) Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): Subtype selective internalization or upregulation. Endocrinology 137: 4046-4049.
34. Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A (1997) Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 272: 13869-13876.
35. Sy RA, Bernstein R, Chynn KY, Kourides IA (1992) Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). J Clin Endocrinol Metab 74: 690-694.
36. Lee EJ, Kim KR, Lim SK, Lee HC, Kim DI, Kim SH, Huh KB (1994) Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). Eur J Endocrinol 131: 109-112.
37. Vance ML, Harris AG (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group. Arch Intern Med 151: 1573-1578.
38. Ezzat S, Horvath E, Harris AG, Kovacs K (1994) Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 79: 113-118.
39. George SR, Kovacs K, Asa SL, Horvath E, Cross EG, Burrow GN (1987) Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma. Clin Endocrinol (Oxf) 26: 395-405.
40. Spinas GA, Zapf J, Landolt AM, Stuckman G, Froesch ER (1987) Pre-operative treatment of 5 acromegalics with a somatostatin analogue: Endocrine and clinical observation. Acta Endocrinol (Copenh) 114: 249-256.
41. Buscail L, Eseve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N, Sucini C (1995). Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92: 1580-1584.
42. Srikant CB (1995) Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochem Biophys Res Commun 209: 400-406.
43. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93: 1321-1325.
44. Lamberts SW, Van der Lely AJ, de Herder WW, Hofland LJ (1996) Drug therapy. Octreotide. New Engl J Med 334: 246-254.
45. Plöckinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ (1997) Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 136: 369-376.
46. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99: 789-798.
47. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67: 1040-1048.
48. Lucas-Morante T, Garcia-Uria J, Estrada J, Saucedo G, Cabello A, Alcaniz J, Barcelo B (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81: 10-14.
49. Stevenaert A, Beckers A (1996) Presurgical octreotide: Treatment in acromegaly. Metabolism 45: Suppl 1: 72-74.
50. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM (1994) Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 40: 421-428.